← boardnext 2026-12next 2028-01
MDGL
Madrigal Pharmaceuticals, Inc.distress 3/10 · well-funded / low risk$530.84-1%today-12% from 52w high
Lead: MASH - Metabolic Dysfunction-Associated Steatohepatitis · est. market ~$10B (approx, global)
Revenue
$311M
Liquidity
$227M
Runway
0.8 yrs
Shares 1y
+3%
Price & events
+6.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-2.7%
1W
+3.4%
1M
+2.3%
3M
+10.5%
6M
+73.0%
1Y
+89.9%
2Y
+498.5%
5Y
+383.6%
All
Overview
- Market Cap
- $12.24B
- Enterprise Value
- $12.35B
- Volume
- 4.89K
- 52 Week Range
- $290 – $603
- Total Shares
- 23.06M
- Float Shares
- 13.85M
- Short %
- 17.99%
- % Held by Insiders
- 5.68%
- % Held by Institutions
- 107.01%
- RVOL
- 0.01x
- Beta
- -1.06
Pipeline stages · 2 programs
Resmetirom
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MGL-3196
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Resmetirom | NASH, Cirrhosis, Liver | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | Resmetirom | Non-Alcoholic Fatty Liver Disease | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 3 | MGL-3196 | NASH - Nonalcoholic Steatohepatitis | — | active not recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 2 | Resmetirom | MASH - Metabolic Dysfunction-Associated Steatohepatitis | — | recruiting |
Catalyst news & presentations · 3
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondarySYH2086 · Initiate clinical development of oral GLP-1 agonist in combination with Rezdiffra.SEC 8-K
- 2025-07-30partnershipSYH2086 · Exclusive global license from CSPC for SYH2086; $120M upfront, up to $2B milestones, royalties.SEC 8-K
Approved drugs (1)
- REZDIFFRARESMETIROM2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $679 (+28% upside) · 14 analysts
- 2026-06-11B of A SecuritiesNeutral
- 2026-05-13Truist SecuritiesBuy
- 2026-05-07Evercore ISI GroupOutperform
- 2026-05-07Canaccord GenuityBuy
- 2026-05-06HC Wainwright & Co.Buy
- 2026-02-20B of A SecuritiesNeutral
Competitors — MASH - Metabolic Dysfunction-Associated Steatohepatitis
Recent news
- 2026-07-21Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
- 2026-07-21Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan
- 2026-07-21Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com
- 2026-07-21Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan
- 2026-07-21Insider Sale: President and CEO of $MDGL Sells 1 Shares - Quiver Quantitative
- 2026-07-20Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.